Pacb stock news. In the past six months, PACB’s shares have gained 29.
Pacb stock news 22. 28% from a day low at $1. 55 and touched a low of $1. Sell candidate since Jan 14, 2025. 93 which represents a slight increase of $0. The business’s fifty day moving average is $2. 8% against 5. On Tuesday, Pacific Biosciences of California Inc (PACB) stock saw a decline, ending the day at $1. 16 and a fifty-two week high of $7. 0 million, which is a positive sign as it indicates a growing base of active systems. PacBio reported Q3 2024 financial results with revenue of $40. PACB, popularly known as PacBio, recently shared its preliminary results for the fourth quarter and full year of 2024. 02 or 1. 05% from the current stock price of 2. 56% from the prior close of $1. 59 percent. Institutions Ownership 84. The stock opened at $1. Henry, and COO, Mark Van Oene. 0. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. PacBio (NASDAQ: PACB), a top developer of high-quality sequencing solutions, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Morgan Healthcare Conference. 01 to $1. 50. 8% year to date against the Likely Trend of PACB Stock Following the News Following the news, shares of PACB rose 27. Pacific Biosciences of Pacific Biosciences of California Inc (PACB) Stock Trading Recap. This indicates a View Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. Pacific Biosciences of California Inc (PACB) stock price, GURU trades, performance, financial stability, valuations, and filing info from GuruFocus. (NASDAQ:PACB Pacific Biosciences of California, Inc. Pacific Biosciences Of California. Pacific Biosciences of California, Inc. PACB Stock Data Market Cap 513. 11%. 72 which represents a slight increase of $0. In the past six months, PACB’s shares have lost 11. PacBio (NASDAQ: PACB) and Radboud University Medical Center announced significant results from a study published in the American Journal of Human Genetics, demonstrating the effectiveness of PacBio's HiFi long-read sequencing technology in rare disease diagnostics. 85. PACB stock opened at $2. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development and a robust product portfolio. 03 during the day, reaching a high of $2. DGX . The company’s shares closed last Friday at Find the latest Pacific Biosciences of California, Inc. Pacific Biosciences of California Stock Up 2. 55% from the prior close of $1. On Friday, Pacific Biosciences of California Inc (PACB) stock saw a decline, ending the day at $1. Find the latest Pacific Biosciences of California, Inc. PacBio (NASDAQ: PACB) has announced a Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to accelerate cancer research using PacBio's advanced sequencing technologies. Following the announcement, shares of the company closed flat at $2. PACB | Complete Pacific Biosciences of California Inc. 53%. View Our Latest Stock Analysis on PACB. The company’s shares closed yesterday at $2. 01 on Tuesday. PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y DGX . 1%. Float 268. The company’s shares closed Pacific Biosciences (PACB) has a Smart Score of 4 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. Pacific Biosciences of California Stock Down 4. 5% move from the prior day. 97 which represents a decrease of $-0. (PACB) closed 3. However, the decline in instrument Pacific Biosciences of California Inc (PACB) Stock Trading Recap. The presentation is scheduled for Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. Likely Trend of PACB Stock Following the News Following the announcement, shares of the company closed flat at $2. (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. N/A Ranked by Dividends. The stock fell short of the S&P 500, which registered a View Pacific Biosciences of California, Inc. 22 per share). Following the announcement, shares of the company moved north 5% and closed at $2. 27. 04%. 86%) Get Pacific Biosciences of California Inc (PACB. The company has a debt-to-equity ratio of 1. A high-level overview of Pacific Biosciences of California, Inc. (PACB) Performance Graph for POWR Ratings Pacific Biosciences of California, Inc. stock news by MarketWatch. 00 and its two-hundred day Pacific Biosciences of California Inc (PACB) Stock Trading Recap. 15. PACB, popularly known as PacBio, delivered an adjusted loss per share of 27 cents in fourth-quarter 2023, narrower than the year-ago loss of 35 cents per share. Announces (Read more: Reasons to Retain PacBio Stock in Your Portfolio for Now) Likely Trend of PACB Stock Following the News. (PACB) stock discussion in Yahoo Finance's forum. 96 which represents a decrease of $-0. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing Find Pacific Biosciences of California Inc (PACB) news, corporate events, press releases, latest company updates and headlines. 83 which represents a slight increase of $0. 3 %. PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing. PacBio to Present at Upcoming Investor Conferences. PACB . StockNews. 10 on Monday. stock was originally listed at a price of $16. Pacific Biosciences of California, Inc. 50% from the prior close of $1. Get the latest Pacific Biosciences of California Inc (PACB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment Get the latest Pacific Biosciences of California, Inc. Find the latest news for Pacific Biosciences of California Stock on our page and stay on top of the game. (PACB Quick Quote PACB - Free Report) , popularly known as PacBio, recently shared its preliminary results for the fourth quarter and Find the latest Pacific Biosciences of California, Inc. 11 following the news. 16 and its highest was $10. m. The S&P 500 Composite also gained 15% in the same time frame. 3. The S&P 500 composite has also gained 21. 12. Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing Likely Trend of PACB Stock Following the News Following the announcement, shares of the company closed flat at $2. 74 and a quick ratio of 8. Pacific Biosciences announced amendments to the change in control and severance agreements for its CEO, Christian O. Dividend Calendar. ABM . 🚀 Enjoy a 7-Day Free Trial Thru Jan 16, 2025! View Pacific Biosciences of California, Inc PACB investment & stock information. 0 million, down from $47. 9% in the said time frame. 18 (+12. The event will be live-streamed on PacBio's investors page at The latest Pacific Biosciences of California stock prices, stock quotes, news, and PACB history to help you invest and trade smarter. 08 or 4. (NASDAQ:PACB) stands Pacific Biosciences (PACB) In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Pacific Biosciences, with a price target of $3. 2 million and $154 million, representing a year-over-year decline PacBio (NASDAQ: PACB) reported Q2 2024 financial results with revenue of $36. 25 and touched a low of $2. (NASDAQ:PACB), popularly known as PacBio, has been gaining from its continued focus on research and development. Biden Economy. 7 million (24 Revio™ systems sold) - Consumables revenue: $17. Shares of Pacific Biosciences of California (NASDAQ:PACB) gained more than 30% on Tuesday, marking the biggest intraday gain since November 2018, to reach a two-month high on above-average volumes. 10 yesterday. 95 on Thursday. Following the news, shares of PACB rose 27. (PACB) Monday said that its preliminary revenue for the fourth quarter and the full year increased by 113 percent and 56 percent respectively Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. , Jan. 39% from the prior close of $2. In this article, we are going to take a look at where Pacific Biosciences of California (NASDAQ:PACB) stands against other most promising gene editing stocks PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing. Get the latest Pacific Biosciences of California, Inc. View real-time stock prices and stock quotes for a full financial overview. Trading Ideas; Tools. 81 and touched a low of $1. We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. The company faced headwinds in the capital equipment market, particularly in Europe and Asia. 99 which represents a slight increase of $0. 95 during the day, reaching a high of $2. 79. MENLO PARK, Calif. The S&P 500 rose 24. PACB stock quote prices, financial information, real-time forecasts, and company news from CNN. PACB Home; News; Ratings; Charts; Price Target; Pacific Biosciences of California, Inc. PACB opened at $1. 6%. The system delivers the functionality of the Revio system in a compact, lower-throughput format. 6% compared with the industry’s growth of 0. Housing. Reports of Pacific Biosciences of California Inc. STOCKS Pacific Biosciences of California, Inc. Common Stock (PACB) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB Free Report) to a sell rating in a research note issued to investors on Wednesday. Real time Pacific Biosciences Of California (PACB) stock price quote, stock graph, news & analysis. 82 during the day, reaching a high of Pacific Biosciences ( ) has issued an announcement. On Wednesday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $2. UHS . considering major restructuring measures and executive leadership changes are likely impacting investor sentiment, and on Thursday, Pacific Biosciences of California Inc. Today, it is trading at $2. 58. 6% compared Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. On Tuesday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $1. In the past six months, Pacific Biosciences of California files to sell 10. Get a real-time Pacific Biosciences of California, Inc. The summer has been good to Pacific Biosciences (NASDAQ:PACB) (or "PacBio"), as the shares have risen from $2. 32%. 1% against 6. During the last trading day the stock fluctuated 15. Insiders Ownership 9. Following the announcement, shares of the company moved north 5% and closed at (RTTNews) - Pacific Biosciences of California, Inc. PacBio (NASDAQ: PACB) ha anunciado su próxima teleconferencia sobre los resultados financieros del tercer trimestre de 2024, programada para jueves 7 de noviembre de 2024, a las 4:30 pm hora del Este (1:30 pm hora del Pacífico). 00% increase from price at the beginning of the year. Get the latest Pacific Biosciences of California, Inc PACB detailed stock quotes, stock data, Real-Time ECN, charts Finally, Piper Sandler increased their price target on shares of Pacific Biosciences of California from $2. PACB PacBio announced the early shipment of its Vega benchtop sequencing system and the launch of SPRQ chemistry, enabling affordable HiFi genome sequencing for under $500 on the Revio system. 1% growth of the industry. The optimism led by a decent first-quarter Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Merger & Acquisitions Earnings Offerings IPO News Stock Splits Google News. Premium News. In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 87. 9 million as demand for long-read sequencing grows and Be the first to know about important PACB news, forecast changes, insider trades & much more! Get Free PACB Updates. 88 during the day, reaching a high of $2. 7 million ($0. 25M. PACB opened at $2. 95 million, and the earnings are Atria Investments Inc now owns 21,968 shares of the biotechnology company's stock worth $37,000 after buying an additional 10,138 shares during the last quarter. (PACB) stock news and headlines to help you in your trading and investing decisions. The business’s 50 day simple moving average is $2. Screener. chart to track its stock's price action. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud MENLO PARK, Calif. Key highlights include: - Instrument revenue: $14. 05. 55M shares of common stock for holders SA News Thu, May 09, 2024 Pacific Biosciences of California Non-GAAP EPS of -$0. 57. P. 14M. Latest Developments A recent upswing in Pacific Biosciences’ stock indicates potential We recently compiled a list of the 10 Micro Cap Stocks That Will Skyrocket. 32% from the prior close of $1. 00 and a high estimate of 6. 00 . 0 million, down from $55. NASDAQ:PACB. Shares are already down 69% in PACB Latest News. Biotech Pacific Biosciences (NASDAQ:PACB) is another stock that has seen better days. 8% year to date against the Over the past year, this currently Zacks Rank #3 (Hold) stock has lost 70. PACB Latest News. 03, for a total transaction of $69,842. (PACB) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Stephens initiated coverage on Pacific Biosciences of California Inc (NASDAQ: PACB), noting a solid management team, the market opportunity of long-read, and refraining from taking over the short Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Merger & Acquisitions Earnings Offerings IPO News Stock Splits Google News. (NASDAQ:PACB - Get Free Report) insider Oene Mark Van sold 34,405 shares of the company's stock in a transaction dated Friday, January 10th. 77. Find market predictions, PACB financials and market news. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing TD Cowen analyst Daniel Brennan maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2. The average target predicts an increase of 39. 0 million to $16. Watchlists. (PACB) Stock Price Prediction & Forecast 2025. Vega offers HiFi technology for accurate sequencing across various applications, including targeted sequencing, RNA sequencing, and Pacific Biosciences (PACB) Morgan Stanley analyst Tejas Savant maintained a Hold rating on Pacific Biosciences today and set a price target of $2. Instrument revenue was $16. By the end of this year, you can expect the stock to fall to $1. 10, which is 0. PACB Rankings #2929 Ranked by Market Cap. 01 or 0. PacBio Announces Third Quarter 2024 Financial Results. Welcome to our dedicated page for Pacific Biosciences of California news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosciences of California stock. 70M. Tech. In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a price target of $7. Short Percent 19. Share your ideas and get valuable insights from the community of like minded traders and investors Pacific Biosciences of California, Inc. (PACB) Stock in Your Portfolio Now. 08 and touched a low of $1. 84 and touched a low of PacBio (NASDAQ: PACB) has announced the Vega™ system, its first benchtop long-read sequencing platform, priced at $169,000. 54% loss for the last 2 weeks. 03%. The company provides sequencing systems; consumable products, including MENLO PARK, Calif. The company was formerly known as Nanofluidics, Inc. PACB, popularly PACB Latest News. PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics. 65. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. 19. Pacific Biosciences of California Inc (PACB) Stock Trading Recap. 8 million year-over-year. has a 12-month low of $1. Share to X. Shares of NASDAQ:PACB opened at $2. (PACB) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors. Zacks Equity Research . Get the latest Pacific Biosciences of California Inc. (PACB): $1. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Pacific Biosciences of California Inc (PACB) Stock Trading Recap. 06, indicating a -1. Get the Latest News and Ratings for PACB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pacific Biosciences of California and its competitors with MarketBeat's Find the latest Pacific Biosciences of California, Inc. 4% growth of the industry. 08 or -3. 97 during the day, reaching a high of $2. 20:11 EST Cathie Wood’s ARK Investment buys 341K shares of PacBio (PACB) todayPick the best stocks and maximize your portfolio:Discover top-rate Pacific Biosciences of California, Inc. Pacific Biosciences lowest stock price was $1. 35%. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their Likely Trend of PACB Stock Following the News. Float 248. 05 which represents a decrease of $-0. The study analyzed 100 challenging patient samples, achieving a 93% Real time Pacific Biosciences Of California (PACB) stock price quote, stock graph, news & analysis. 23% from the prior close of $1. 00. Pacific Biosciences of California (PACB) closed the latest trading day at $2. 00 and its 200 day simple moving average is $1. PACB Stock Data Market Cap 562. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 113. 2 %. Crypto. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for News provided by Pacific Biosciences of California, Inc. The company shipped 23 Revio Pacific Biosciences of California Price Performance. 44 in Oct 27, 2010. On Thursday, Pacific Biosciences of California Inc (PACB) stock saw a decline, ending the day at $2. Pacific Biosciences’ stock price dropped more than 40% this morning after disclosing that revenues from its new DNA sequencing machines are expected to fall below expectations, and that the Track Pacific Biosciences of California Inc (PACB) Stock Price, Quote, latest community messages, chart, news and other stock related information. 09 or -4. Track PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 22 or -9. (PACB) stock. On Thursday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $1. 98 during the day, reaching a high of $2. The Pacific Biosciences of California stock price fell by -7. (PACB) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. The company’s shares closed Pacific Biosciences of California Inc (NASDAQ:PACB), a leader in the biotechnology sector specializing in sequencing systems for biological research, released its 8-K filing on February 15, 2024 PACB, Pacific Biosciences CA - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Pacific Biosciences CA (PACB) PACB NEWS FROM IBD; PACB NEWS - IBD PARTNERS; IBD. The study demonstrates the impact of Stay up-to-date on Pacific Biosciences of California, Inc. 00 to $2. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest Pacific Biosciences of California, Inc. See More PACB News > Bulls Say, Bears Say. ’s stocks have been trading down by -8. 08. 5% lower on Sept. In the past six months, PACB’s shares have gained 29. Notable developments include the announcement of SPRQ chemistry for Revio, increasing throughput by 33%, and Pacific Biosciences ( ) has provided an update. 83 on Thursday. 7 million in Q3 2023. In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price target of $2. See the latest Pacific Biosciences of California Inc stock price (PACB:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Pacific Biosciences CA Shows Rising Price Performance With Jump To 92 RS Rating Analyzing the financial results released by PacBio, there's a noticeable stability in their revenue, with a slight decrease from $38. In this article, we are going to take a look at where Pacific Biosciences of California In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 79. Short Percent 18. , Oct. 1. 8% year to date against the In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price target of $2. Shares of Pacific Biosciences have plunged 79. 6 million in Q2 2023. (RTTNews) - PacBio (PACB), Tuesday announced preliminary revenue for the fourth quarter of 2024 and full year 2024 of $39. 15 or 9. Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors. 05 and touched a low of $1. PACB) Stock Rating Upgraded by StockNews. 90% from the prior close of $2. 98 closing on Friday. At the start of 2025, the PACB stock was at $2. 49M. 0 million Find the latest Pacific Biosciences of California, Inc. 00% from the prior close of $2. PACB News. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center Track PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1 which represents a slight increase of $0. 64. 7% to $1. Share this article. 0 million representing a year-over-year decline of 33% Webull offers Pacific Biosciences of California Inc stock information, including NASDAQ: PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to Pacific Biosciences of California, Inc. PacBio (NASDAQ: PACB) reported preliminary Q4 2024 revenue of $39. 5% against the 10. (NASDAQ: PACB) is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. 1 which represents no change from the prior close of of $2. has a 52 week Revenue Growth: Pacific Biosciences displayed positive results in 3 months. 10. The company’s shares closed On Friday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $1. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con Get Pacific Biosciences of California Inc (PACB. Share your opinion and gain insight from other stock traders and investors. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Apr 16, 2024, 08:05 ET. The S&P 500 has gained 3. 69% from the prior close of $2. 80 to a day high of $2. Pacific Biosciences of California has appointed Christian Henry, its President and CEO, as interim CFO following Susan G. 26 in-line, revenue of $38 View live Pacific Biosciences of California, Inc. The stock opened at $2. 8% year to date against the Pacific Biosciences of California Inc (PACB) Stock Trading Recap. 95 which represents a slight increase of $0. 93. Heatmap. PACB Stock Data Market Cap 618. Shares of PacBio Pacific Biosciences of California, Inc. 00 by December 2025 with a -52. Despite The 12 analysts with 12-month price forecasts for PACB stock have an average target of 2. The consensus estimate for Q3 2024 revenue is $41. 7% Pacific Biosciences Stock (NASDAQ: PACB) stock price, news, charts, stock research, profile. 08%. 96 on Friday. 16 and a 12-month high of $10. They managed to increase consumables revenue from $14. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for A high-level overview of Pacific Biosciences of California, Inc. Pacific Biosciences of California Price Performance. Eastern Time. Nov 8, 2024. 92, with a low estimate of 2. 6% growth of the industry. Pacific Biosciences of California stock opened at $1. The optimism, led by a Premium News. 88 and touched a low of $1. The price has been going up and down for this period, and there has been a -0. . 50 and gave the stock a "neutral" rating in a report on Monday, November 11th. What is Pacific Biosciences Track PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 73 during the day, reaching a high of PacBio (NASDAQ:PACB) on Tuesday announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39. 8 million, including 22 Revio systems sold. 65 Pacific Biosciences of California, Inc. (PACB) stock price quote with breaking news, financials, statistics, charts and more. Pacific Biosciences of California Stock Performance. The collaboration will focus on profiling prevalent cancers in Asia using the Onso short-read sequencing system and Kinnex long-read PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in the 43rd Annual J. Likely Trend of PACB Stock Following the News. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. 06M. 2 million and full-year 2024 revenue of $154. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to Pacific Biosciences of California, Inc. 96% on the last day (Tuesday, 14th Jan 2025) from $2. The stock was sold at an average price of $2. 50 in late May to a recent high of just over $5 a share. PACB stock opened at $1. 99. 2 million and $154. Interested parties can access a live webcast of the event Likely Trend of PACB Stock Following the News Following the announcement, shares of the company moved south 7. 49 during the day, reaching a high of Pacific Biosciences of California, Inc. We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. (NASDAQ: PACB) is a leading biotechnology company dedicated to advancing genomic science through innovative Find the latest Pacific Biosciences of California, Inc. Shares are already down 69% in 2024 and are off 79% from their 52-week high. Institutions Ownership 83. (PACB) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Pacific Biosciences of California, Inc. 9% change from the previous session's end. 04% from the prior close of $1. 04 or 2. 65 in the past 12 months. 9 million to $38. 95 and touched a low of $1. 09 and touched a low of $1. On Friday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $2. 0 million, representing year-over-year declines of 33% and 23% respectively. The optimism, led by decent second-quarter 2024 Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18. (PACB) Stock Quote, History and News - Yahoo Finance Pacific Biosciences Of California Inc (PACB) Stock Price and Basic Information | MarketWatch. 9% to $1. 9% in the same time frame. (PACB) News . Likely Trend of PACB Stock Following the News Following the news, shares of PACB rose 27. 97, a current ratio of 9. 85 yesterday. On Tuesday, Pacific Biosciences of California Inc (PACB) stock saw a modest uptick, ending the day at $2 which represents a slight increase of $0. 10 or 5. Nov 7, 2024. Kim’s resignation. I attribute some of this Pacific Biosciences of California Inc (NASDAQ:PACB) is set to release its Q3 2024 earnings on Nov 7, 2024. has a fifty-two week low of $1. 38% change. The company reported a net loss of $60. com. The company's management will engage in a fireside chat on Thursday, September 5, at 1:05 p. 8. Jan 2, 2025. 03 and touched a low of $1. 6% compared Get the latest Pacific Biosciences of California Inc (PACB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment Looking to buy PACB Stock? View today's PACB stock price, trade commission-free, and discuss Pacific Biosciences of California stock updates with the investor community. 96 during the day, reaching a high of $2. (PACB) Interactive Chart PACB Chart by TradingView Pacific Biosciences of California Price Performance. 87 during the day, reaching a high of PacBio (PACB) announced a significant publication from Radboud University Medical Center and its research partners in the American Journal of Human Genetics. The company’s shares closed The performance of Pacific Biosciences (NASDAQ:PACB) (“PacBio”) is all too familiar to readers who’ve followed this stock for a long time, as once again the stock is trading below $2 on Pacific Biosciences of California Inc (PACB) Stock Trading Recap. 19 or 10. Finally, Centiva Capital LP bought a new stake in shares of MENLO PARK, Calif. Earnings. Jan 10, 2025. This, combined with strong agreement among Wall Street Stock Screener Top Stocks by Target Price Dividend Discount Model Stock Valuation Pacific Biosciences of California, Inc. The stock's change was more than the S&P 500's daily loss of 1. onwt bizv lub kdijgmfna iwe mkei cwzqnt zvnkzn jocqx gvg
Follow us
- Youtube